Trial Profile
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Acronyms TAHOE
- 20 Aug 2014 New source identified and added (ClinicalTrials.gov: US National Institutes of Health - NCT00886795).
- 20 Aug 2014 New trial record